Free tool
FAERS Monitor: Femring
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021367 or its brand name (Femring, Estradiol Acetate). Reports on generic versions are filed under their own applications.
Reports
780
Serious
162
21% of reports
Hospitalization
51
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective176
- hot flush126
- therapeutic product effect decreased101
- device expulsion61
- headache51
- insomnia38
- night sweats35
- vaginal haemorrhage35
- vulvovaginal discomfort35
- product use in unapproved indication32
- fatigue31
- off label use31
- product dose omission issue30
- feeling abnormal29
- nausea28
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 20 |
| 2006 | 11 |
| 2007 | 23 |
| 2008 | 6 |
| 2009 | 10 |
| 2010 | 8 |
| 2011 | 8 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 7 |
| 2015 | 15 |
| 2016 | 80 |
| 2017 | 68 |
| 2018 | 70 |
| 2019 | 76 |
| 2020 | 35 |
| 2021 | 48 |
| 2022 | 49 |
| 2023 | 45 |
| 2024 | 50 |
| 2025 | 81 |
| 2026 | 44 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,379 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal discomfortSignal | 35 | 215.2 | 155.5 | 7,195 |
| therapeutic product effect decreasedSignal | 101 | 60.9 | 50.8 | 5,894 |
| hot flushSignal | 126 | 45.2 | 38.5 | 5,407 |
| night sweatsSignal | 35 | 29.3 | 21.2 | 930 |
| device expulsionSignal | 61 | 25.4 | 19.9 | 1,408 |
| vaginal haemorrhageSignal | 35 | 21.8 | 15.7 | 673 |
| insomniaSignal | 38 | 3.8 | 2.8 | 78 |
| drug ineffectiveSignal | 176 | 3.6 | 3.2 | 350 |
| product use in unapproved indicationSignal | 32 | 3.5 | 2.5 | 55 |
| feeling abnormalSignal | 29 | 3.3 | 2.3 | 44 |
| product dose omission issueSignal | 30 | 2.8 | 1.9 | 32 |
| headacheSignal | 51 | 2.2 | 1.7 | 33 |
| fatigue | 31 | 1.1 | 0.8 | 0 |
| off label use | 31 | 1.0 | 0.7 | 0 |
| nausea | 28 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.